Thomas Steyer’s ARS Pharmaceuticals SPRY Stock Holding History

Thomas Steyer’s Portfolio SPRY Stock Details SPRY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-47,620	Closed	-$2.21M	–	247
2020 Q4	$2.21M	Buy	+47,620	New	+$1.59M	0.01%	133

Other funds holding SPRY

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Thomas Steyer's SPRY Position: Q1 2021 in Review

Thomas Steyer sold out of ARS Pharmaceuticals (SPRY) in Q1 2021, closing a stake of 47,620 shares — an estimated $2.21M sold.

Thomas Steyer first reported a position in SPRY in Q4 2020 and held it in 1 quarter. The position peaked at $2.21M in Q4 2020. 68 funds tracked by Wall St. Rank hold SPRY as of Q1 2021.

Thomas Steyer reported no remaining ARS Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
Thomas Steyer sold 47,620 ARS Pharmaceuticals shares in Q1 2021, an estimated $2.21M.
Thomas Steyer first reported a position in ARS Pharmaceuticals in Q4 2020 and held it in 1 quarter.
Thomas Steyer's ARS Pharmaceuticals position peaked at $2.21M in Q4 2020.
68 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q1 2021.

Based on Farallon Capital Management's 13F filing for Q1 2021, filed 17 May 2021.